Administration of azole antifungals to tacrolimustreated solid organ recipients results in a major drug-drug interaction characterized by increased exposure to tacrolimus. The magnitude of this interaction is highly variable but cannot currently be predicted. We performed a retrospective analysis of 126 solid organ recipients (95 lung, 31 kidney) co-treated with tacrolimus and voriconazole (n = 100) or posaconazole (n = 26). Predictors of the change in tacrolimus dose-corrected trough concentrations (C/ D) between baseline and tacrolimus-azole co-therapy were assessed using linear mixed modeling. Patients were genotyped for relevant polymorphisms in CYP3A4, CYP3A5, MDR1, CYP2C19, POR, and UGT1A4. Tacrolimus C/D increased by a factor 5.0 AE 2.7 (range 1.0-20.2) for voriconazole and 4.4 AE 2.6 (range 0.9-18.0) for posaconazole, suggesting that a 66% dose reduction is insufficient for the majority of patients. Change in C/D was blunted in CYP3A5 expressors (estimated effect: -43%, p = 0.017) and affected by hematocrit (+8% per %, p = 0.004), baseline C/D (-14% per 100% increase, p < 0.001), and age (+1%, p = 0.008). However, the final model explained only 22% of interindividual variability in C/D change. In conclusion, CYP3A5 genotype and several clinical variables were identified as modulators of the tacrolimus-azole interaction, but these did not permit accurate predictions in individual patients.
Introduction
Invasive aspergillosis occurs in 0.1-3.5% of solid organ recipients and has a particularly high incidence in lung transplant recipients (1) . First-line treatment commonly consists of the antifungal agent voriconazole or, less commonly, posaconazole or isavuconazole. Voriconazole use is complicated by highly variable pharmacokinetics resulting from metabolism that is saturable and subject to genetic variability, as well as the influence of drugdrug interactions (DDIs), patient age, and hepatic dysfunction (2) . The first-pass and systemic metabolism of voriconazole are mediated by cytochrome P450 (CYP) enzymes CYP2C19, -2C9, -3A4, and -3A5 and the flavincontaining monooxygenases FMO1 and -3, present in enterocytes as well as hepatocytes (3, 4) . All of these enzymes display genetic heterogeneity. In particular, single nucleotide polymorphisms (SNPs) in the CYP2C19 gene have been associated with loss of function (CYP2C19*2 and CYP2C19*3) or gain of function (CYP2C19*17) (2) . CYP2C19 genotype has a clear effect on voriconazole exposure in healthy volunteers (5) (6) (7) . Although this relationship is much less pronounced in patients, both voriconazole trough concentrations and treatment success rates are higher in CYP2C19 poor metabolizers (8) . SNPs in CYP3A4/5 seem of limited importance to voriconazole (9, 10) ; genetic variability in CYP2C9 has no clear effect (9) (10) (11) . Posaconazole, by contrast, is largely excreted unchanged. About 17% of the administered dose undergoes biotransformation, which is primarily mediated by UDP-glucuronosyl transferase UGT1A4, but not by CYP enzymes (12, 13) .
Voriconazole and posaconazole are not only substrates, but also potent inhibitors of CYP3A4 (among other enzymes and pumps) (14) (15) (16) (17) . As a result, both drugs strongly increase exposure to a variety of CYP3A4 substrates including the calcineurin inhibitors cyclosporine and tacrolimus (Tac) (3, 18) . When initiating voriconazole or posaconazole in a patient taking Tac, the drug package inserts recommend reducing the dose of Tac by 66% and monitoring Tac trough concentrations (3, 18) . Nevertheless, the magnitude of DDI is highly variable and the aforementioned a priori dose adjustment can still result in significant Tac overdosing (19) , which is likely related to the fact that, as for voriconazole and posaconazole, Tac disposition is complex and influenced by several clinical and genetic factors. Tac is a substrate for CYP3A4/5 and P-glycoprotein (P-gp). Patients possessing two lossof-function alleles for CYP3A5 (so-called "CYP3A5 nonexpressors") have 50% lower Tac dose requirements compared with "CYP3A5 expressors" (20) . Similarly, the loss-of-function CYP3A4*22 SNP is associated with significantly reduced Tac clearance (21, 22) . Polymorphisms in the gene coding for P-gp (MDR1), however, seem to have only limited effects on Tac disposition (23, 24) .
There is convincing in vitro evidence that the CYP3A5 enzyme is intrinsically resistant to enzymatic inhibition (e.g. by voriconazole [25, 26] ). We have previously shown that the moderately potent CYP3A4 inhibitor fluconazole does not seem to have an effect on Tac disposition in CYP3A5 expressors, whereas it does in CYP3A5 nonexpressors (27) . This raises the question of whether the DDI between Tac and newer triazole antifungals could also be, in part, genetically determined. In addition, clinical factors could be relevant. For example, it is likely that the effect of voriconazole on Tac disposition is blunted in patients already taking a CYP3A4 inhibitor. Likewise, high-dose corticosteroids induce CYP3A4 and may modulate the DDI, as may the presence of anemia (which increases hepatic Tac clearance [28] ) and hepatic dysfunction.
The aim of this study was to retrospectively identify genetic and clinical predictors of the magnitude of DDI between Tac and voriconazole or posaconazole in a cohort of renal and lung recipients.
Materials and Methods

Study design and population
This was a multicenter retrospective cohort analysis. Electronic hospital records of the University Hospitals Leuven were queried to identify renal and lung recipients treated with the combination of Tac (29) . Estimated glomerular filtration rate (eGFR) was calculated using the chronic kidney disease epidemiology (CKD-EPI) formula and based on serum creatinine at the start of azole therapy. Hepatic dysfunction was defined as serum alanine aminotransferase >3 times the upper limit of normal, total bilirubin >2 mg/dL, or known hepatic cirrhosis at the start of azole therapy. All patients provided written informed consent. This study was approved by the ethics committee of the University Hospitals Leuven (S53364).
Genotyping and haplotype inference
Genomic DNA was isolated from whole blood samples using a salting-out procedure (30) , from explanted recipient lung tissue, or using the MagNa Pure kit (Roche, Basel, Switzerland; Leiden cohort only). The quantity and quality of genomic DNA were verified with a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA) before being assayed on an OpenArray platform (Life Technologies, Carlsbad, CA). The following SNPs were tested: CYP3A5*3 (rs776746), CYP3A4*22 (rs35599367), CYP3A4*1b (rs2740574), CYP2 C19*2 (rs4244285), CYP2C19*3 (rs4986893), CYP2C19*17 (rs12248560), MDR1 3435C>T (rs1045642), MDR1 2677G>A/T (rs2032582), MDR1 1236C>T (rs1128503), POR*28 (rs1057868), FMO1 (rs742350), FMO3 (rs1800822), and UGT1A4*2 (rs6755571). Only four patients carried the MDR1 2677 A allele and these were grouped with T alleles for all analyses. Genotyping for CYP2C19*3 failed (call rate 0%). Overall call rate for the other SNPs was 88.5%, mainly due to 14 lung recipients for which DNA (extracted from lung tissue) was suboptimal. Call rate in the other 112 patients was 96.2%: only these were used for linkage disequilibrium and haplotype analysis. CYP3A5*3/*1 and *1/*1 patients were grouped for analyses ("CYP3A5 expressors") as were CYP3A4*1/*22 and *22/*22 patients ("CYP3A4*22 carriers"), unless otherwise specified. Hardy-Weinberg equilibrium and linkage disequilibrium between SNPs were assessed using Haploview (31) . Haplotypes were inferred using the program PHASE version 2.1 (32) .
Statistical analysis
Data are presented as mean AE standard deviation except when stated otherwise. Normality was tested using the Shapiro-Wilk test. C/D was not normally distributed and log-transformed for analysis, as was the change in C/D between the periods with and without azole co-therapy. Two main outcome parameters were studied: (1) Tac C/D at any time point and (2) 
Results
Study population and tacrolimus dose changes A total of 126 eligible patients were identified, for whom 1206 Tac C/D values were available (552 during azole co-therapy). Characteristics of the study population are summarized in Table 1 . The indication for azole therapy was proven or suspected fungal infection in all patients. Among lung recipients, 27 had cystic fibrosis and 21 of these (78%) were treated with pancreatic enzyme supplements for fat malabsorption. Daily Tac dose was reduced by a factor of 5.0 AE 3.3 (range 0.6-25.0) during voriconazole and 3.7 AE 2.0 (range 0.7-10.0) during posaconazole therapy, compared with baseline. On average, Tac DC/D between baseline and azole co-therapy was 5.0 AE 2.7 (range 1.0-20.2) for voriconazole, and 4.4 AE 2.6 (range 0.9-18.0) for posaconazole. Figure 1 shows the time-related change in C/D during azole therapy for those patients in whom a mean pre-azole C/D was available (82% of study population).
A separate analysis was performed on the subgroup of patients for whom the baseline Tac C/D was collected before (rather than after) azole initiation and for whom at least 1 Tac C/D was available in the second week (day 8-14) after azole initiation. In these patients (n = 68), the change in Tac dose between the period immediately before azole initiation and immediately after reaching a new Tac steady state could be assessed. Figure 2 shows changes in Tac dose and C/D in this subgroup. For posaconazole, Tac dose decreased more than fourfold in 6/12 (50%) of patients; C/D increased more than fourfold in 5/12 (42%). For voriconazole, Tac dose decreased more than fourfold in 36/56 (64%) of patients; C/D increased more than fourfold in 30/56 (54%).
Five patients were treated with a moderate-to-potent CYP3A4 inhibitor (diltiazem, n = 3; verapamil, n = 1; erythromycin, n = 1) and three were treated with a potent CYP3A4 inducer (carbamazepine, n = 2; rifampicin, n = 1). In all of these patients, the inhibitor/inducer was taken at the same dose during the entire study period (before, during, and after azole co-therapy). In patients treated with an inhibitor, mean Tac DC/D was only 2.1 AE 1.2 (range 1.0-6.3). On average, hematocrit reached a nadir around the time of azole initiation, after which it increased (Figure 3 ). One week after azole discontinuation (and Tac dose increase), Tac concentration was >15 ng/lL in only two patients (16.1 and 16.5 ng/mL).
Genetics
All SNPs were in Hardy-Weinberg equilibrium. A full list of genotype frequencies, MDR1 haplotypes, and functional diplotype categories is presented in Tables S1-S3 , available online. One voriconazole-treated patient was both CYP3A5*3/*1 and CYP3A4*1/*22, and was 
Determinants of C/D over time
Predictors of C/D are presented in Table 2 . The estimated effect indicates the change in C/D that is expected to occur with a 1-unit increase in (or presence of) the predictor variable, when all other predictors are held constant. For the whole patient group, C/D increased as a result of azole therapy, presence of CYP3A4*22, and increasing hematocrit. Use of other CYP3A4 inhibitors was associated with a trend towards lower C/D. Conversely, C/D was lower in CYP3A5 expressors, and this effect was accentuated in homozygous CYP3A5*1/*1 carriers. Figure 4 shows the change in C/D after azole initiation by CYP3A4/5 genotype categories. This analysis confirms the relevance of several known determinants of Tac disposition in a setting subject to very important clinical variability, but provides no information as to whether these factors also modulate DDI magnitude. To address that question, a model was constructed for the outcome parameter of DC/D between baseline and azole co-therapy (Table 3) The final model explained 22% of interindividual variability in DC/D. Model fit is shown in Figure 5 . It must be noted that hematocrit was only predictive when considered as a time-varying fixed effect: The single baseline value for hematocrit did not predict DC/D (p = 0.153). The magnitude of DDI was smaller both in patients treated with a CYP3A4 inducer and those treated with a CYP3A4 inhibitor in unadjusted analysis ( Figure 6 ) but, in multivariable analysis, only the effect of inhibitors remained borderline significant. This is likely related to the small number of patients treated with a CYP3A4 inducer. The abovementioned analyses consider all C/D values between days 8 and 90 of azole co-therapy. Sensitivity analyses were performed in which the model for DC/D was run using different time windows (i.e. days 4-90, 14-90, and 8-30). The results of these were identical to those of the primary analysis except for the days 8-30 interval, in which age was no longer significant (p = 0.097, data not shown). Whether or not azole TDM was performed did not predict DDI magnitude. Additionally, the model for DC/D was repeated in the subgroups with and without TDM and is presented in Table S4 .
Results were comparable to the full cohort analysis, although loss of significance was noted for some predictors, which may have been related to lower statistical power in the subgroups.
Conclusion
This retrospective analysis of 126 solid organ recipients is the largest attempt to date to systematically assess factors governing the magnitude of interaction between oral Tac and voriconazole or posaconazole. The proportional increase in Tac C/D (DC/D) resulting from azole co-therapy varied widely (almost 20-fold) between patients, in line with what has been previously observed in allogeneic hematopoietic stem cell transplantation (33) . This degree of increase in Tac C/D was modulated by CYP3A5 genotype, age, baseline C/D, and hematocrit, all of which are biologically plausible. Firstly, the CYP3A5 enzyme is intrinsically more resistant to inhibition compared to CYP3A4 (25, 26) , which is consistent with a previously observed lack of DDI between Tac and fluconazole (a moderate inhibitor) in CYP3A5 expressors (27) . In the current analysis, CYP3A5 expressors were relatively resistant to the effect of voriconazole/ posaconazole, albeit to a highly variable degree. Secondly, the effect of increasing age on DDI magnitude may partly be related to greater voriconazole exposure resulting in more pronounced CYP3A4 inhibition, as voriconazole area under the curve has previously been demonstrated to be 86% higher in elderly versus young healthy volunteers (3). Thirdly, DDI magnitude was reduced in patients with high baseline Tac C/D and those using another CYP3A4 inhibitor (nonsignificant trend for the latter). These variables are mechanistically related. If CYP3A4 expression/activity is already low (resulting in high Tac C/D) or inhibited by a drug like diltiazem, the proportional effect of adding an azole is likely to be diminished. Indeed, past a certain degree of inhibition, CYP3A4 is functionally absent and additional inhibitors are expected to have little extra effect. Finally, Tac is highly bound to red blood cells, which shield it from hepatic extraction (34) . As a result, a 10% absolute decrease in hematocrit may increase Tac clearance by more than 50-100%, an effect size similar to being a CYP3A5 expressor (35, 36) . This corresponds quite well with the effect size in the current analysis (an absolute increase of hematocrit from 30% to 40% was predicted to result in an 80% increase in DC/D). It is important to note that hematocrit was the only time-varying factor that was retained in the final model and therefore the only factor that could change between baseline and azole co-therapy in individual patients. Changes in hematocrit resulted in changes in C/D (and therefore DDI magnitude), but baseline hematocrit was not a significant determinant of DDI magnitude. Consequently, when an azole is initiated in a Tac-treated patient, hematocrit will not have predictive value regarding the DDI, because that would essentially require knowledge about how hematocrit will change in the future. It is prudent, however, to monitor Tac concentration relatively frequently in patients who are anemic at azole initiation, because Tac dose requirements will continue to decrease as hematocrit recovers (which may take months). Effect sizes for the abovementioned DDI determinants were modest and the estimates were imprecise. Many very pronounced as well as almost absent DDIs could not be accurately predicted ( Figure 5 ). Consequently, while the Tac-azole DDI seems to be blunted in CYP3A5 expressors, the current results do not suggest that it would be useful to prospectively genotype patients in order to tailor Tac dose reduction upon azole initiation. Its effect, like that of the other predictors, is simply not consistent enough.
After adjustment for relevant covariables, posaconazole and voriconazole resulted approximately in a 2.7-fold to 3.6-fold increase in Tac C/D, respectively ( Table 2) . These values correspond relatively well with the threefold change originally observed in healthy volunteers, which resulted in the current Tac dose reduction recommendation of 66% upon voriconazole/posaconazole initiation. However, these are adjusted, model-predicted effects. Actual increases averaged 4.4-fold to 5.0-fold, partly due to a gradual increase in hematocrit over time (which also increases C/D). A comparison limited to the periods immediately prior to azole initiation and 2 weeks after azole initiation revealed that Tac C/D increased more than fourfold in 57% of voriconazole-and 42% of posaconazole-treated patients. This would suggest that, particularly for voriconazole, an a priori dose reduction of 66% will be insufficient for more than half of all patients. A reduction of 75% might be more appropriate for voriconazole, depending on whether the clinician judges the slightly increased risk of underdosing to be acceptable in a particular patient. Conversely, a 50% initial Tac dose reduction is likely to be appropriate in patients already treated with a CYP3A4 inhibitor, based on the limited number of such patients included in the current analysis. However, it remains difficult to formulate general dosing recommendations given the very high range of DC/D between patients.
Several limitations must be noted. Firstly, data regarding azole trough concentrations were not included. Azole TDM did not become routine in our institutions until several years into the study period and was performed in only 30% of all (mostly voriconazole-treated) patients. Additionally, the frequency of TDM varied significantly between time periods and departments. Rather than include highly sporadic data regarding voriconazole trough concentrations, we included as a variable whether azole TDM was not performed (which should result in quite variable azole exposure between patients) or was (which should result in more comparable exposure between patients). However, azole TDM was not predictive of any outcome parameter. Secondly, Tac disposition is inherently variable in the setting of invasive fungal infections and not all relevant factors can be corrected for (e.g. diarrhea, noncompliance). This clinical variability may obscure the effects of subtle determinants and increases model imprecision. It has, for example, been shown that the CYP2C19 genotype modulates the magnitude of DDI between Tac and voriconazole in healthy volunteers (37) . The current analysis, however, calls into question whether that effect is clinically meaningful in actual patients. Thirdly, the number of tested SNPs in relevant enzymes and transporters was limited, mainly to those with an unambiguous effect on Tac or voriconazole disposition in whites. Many more SNPs could be considered, such as numerous SNPs in FMO1 and -3 (38,39), although it is not known whether these affect voriconazole disposition. Furthermore, the effect of SNPs in enzymes relevant to azole disposition (CYP2C19, FMO, UGT1A4) is expected to diminish by the application of azole TDM, which results in more comparable exposure between patients and is becoming common practice in many centers, including ours. In the future, it could be interesting to perform a prospective study limited to patients in whom azole TDM is performed, which would allow more formal pharmacokinetic modeling for both tacrolimus and the azole. Fourthly, CYP2C19*3 genotyping failed, although this is unlikely to be a significant limitation as its allelic frequency among whites is very low (40).
In conclusion, CYP3A5 genotype and several clinical variables were identified as biologically plausible modulators of the magnitude of DDI between Tac and voriconazole or posaconazole. Other well-characterized genetic polymorphisms in the primary metabolic pathways of these drugs had no effect. Ultimately, most interindividual differences in susceptibility to the Tacazole DDI remain unexplained. Based on currently available evidence, it is not yet possible to individually tailor reductions in Tac dose when voriconazole or posaconazole is initiated.
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